{"id":"dmab-discontinuation-and-switching","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical femoral fractures"},{"rate":null,"effect":"Rebound bone loss after discontinuation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), thereby reducing osteoclast formation and bone resorption. This study investigates what happens when patients discontinue DMAB therapy or switch to alternative treatments, monitoring for rebound bone loss and fracture risk. The research aims to establish optimal management strategies for patients who cannot continue or tolerate denosumab therapy.","oneSentence":"This is a clinical study protocol examining the safety and efficacy of discontinuing or switching from denosumab (DMAB), a RANKL inhibitor used for bone loss prevention.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:55.941Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Bone loss in patients with cancer receiving hormone-deprivation therapy"},{"name":"Giant cell tumor of bone"}]},"trialDetails":[{"nctId":"NCT04177940","phase":"PHASE4","title":"Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-17","conditions":"Osteoporosis","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"DMAB Discontinuation and Switching","genericName":"DMAB Discontinuation and Switching","companyName":"University of Alabama at Birmingham","companyId":"university-of-alabama-at-birmingham","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a clinical study protocol examining the safety and efficacy of discontinuing or switching from denosumab (DMAB), a RANKL inhibitor used for bone loss prevention. Used for Osteoporosis in postmenopausal women, Bone loss in patients with cancer receiving hormone-deprivation therapy, Giant cell tumor of bone.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}